Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial drug, CPI-613
PLoS Medicine,
by Moises O. Guardado Rivas, Shawn D. Stuart, Daniel Thach, Michael Dahan, Robert Shorr, Zuzana Zachar, Paul M.